This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Nature Reviews Cardiology, Published online: 14 April 2025; doi:10.1038/s41569-025-01150-1 In this Review, Liu, Yang and He explore the diverse mechanisms by which various post-translational protein acylations, and the dynamic interactions between them, contribute to cardiac hypertrophy. The authors also discuss the therapeutic potential of targeting acylations to modulate their effects on chromatin architecture, enzyme activity and metabolic pathways.
Dr. Prateek Bhatnagar, the best cardiac surgeon in India, operated a 68-year-old gentleman from Bengal, who had been refused coronary bypass surgery by leading cardiac centers across India, due to the high-risk nature of his condition. The patient had a critically low pumping of heart (left ventricular ejection fraction) of just 22%, indicating severely compromised heart function.
Circulation, Volume 151, Issue 15 , Page 1111-1125, April 15, 2025. Heart failure is a growing health-care concern affecting tens of millions of individuals globally. Although traditional therapeutic strategies have focused on reducing the risk for hospitalization and mortality, the importance of patient-reported outcomes (PROs) in patients with heart failure is increasingly being recognized.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Nature Reviews Cardiology, Published online: 14 April 2025; doi:10.1038/s41569-025-01158-7 Two clinical trials presented at the ACC.25 describe the expanding indications for the glucagon-like peptide 1 receptor agonist semaglutide in patients with type 2 diabetes mellitus.
The assessment of left ventricular (LV) diastolic function based on the American Society of Echocardiography and the European Association of Cardiovascular Imaging (ASE/EACVI) guidelines requires measurement o.
The assessment of left ventricular (LV) diastolic function based on the American Society of Echocardiography and the European Association of Cardiovascular Imaging (ASE/EACVI) guidelines requires measurement o.
Anemia correction reduced perioperative rates but showed no significant impact on postoperative outcomes, emphasizing the need for prehabilitation strategies.
Atrial fibrillation (AF) is a major cause of stroke, with dynamic thromboembolic risk during and shortly after episodes. Implantable cardiac monitors (ICMs) and wearable devices have emerged as tools for real-time AF detection, yet their comparative performance in supporting anticoagulation strategies remains underexplored.
In patients undergoing transcatheter aortic valve replacement (TAVR), the risk of delayed atrioventricular block (AVB) in those without procedural conduction disturbances (CDs) remains largely unknown. This may impact hospital stay, particularly same- or next-day discharge following the procedure.
The beneficial effects of finerenone in patients with heart failure (HF) and mildly reduced or preserved ejection fraction were consistent, regardless of a history of chronic obstructive pulmonary disease (COPD) status. BMI, body mass index; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide. Aims Chronic obstructive pulmonary disease (COPD) is associated with worse outcomes in heart failure (HF) with mildly reduced or preserved ejection fraction (HFmr
Compare these 2 tracings. Is one or both of them 3rd-Degree ( Complete ) AV Block? If not Why not? Figure-1: Is one or both of these tracings 3rd-Degree? Let's look at these rhythms one at a time starting with Rhythm-B: Rhythm B ( which I have reproduced in Figure-2 ): As always I favor the P s, Q s, 3 R Approach for assessing rhythm disorders, as I find this the most time-efficient way to narrow down my differential diagnosis of arrhythmias ( See ECG Blog #185 ): NOTE # 1: Lead MCL-1 is a ri
Aims The prognostic significance of detecting left ventricular (LV) systolic dysfunction during family screening programmes (FSPs) in relatives of probands affected by dilated (DCM) and non-dilated left ventricular (NDLVC) cardiomyopathies remain unclear. This study sought to evaluate the prognostic role of LV systolic dysfunction detection in relatives of DCM/NDLVC probands and to define the most accurate FSP.
A man in his early 30s was walking when he developed central chest pain which was non-radiating, then had a syncopal event with bowel incontinence, and when he woke up he had ongoing chest pain. Notes never having symptoms like this before, pain is so severe its causing SOB. He called 911. Medics recorded a BP of 79/52 with pulse of 47. They recorded this ECG: Obvious inferior STEMI/OMI What else?
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
64 
Let's personalize your content